ALVO Stock - Alvotech
Unlock GoAI Insights for ALVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $489.68M | $91.43M | $83.03M | $36.77M | $66.62M |
| Gross Profit | $304.37M | $-69,422,000 | $18.93M | $36.77M | $66.62M |
| Gross Margin | 62.2% | -75.9% | 22.8% | 100.0% | 100.0% |
| Operating Income | $69.64M | $-354,860,000 | $-346,442,000 | $-235,456,000 | $-137,537,000 |
| Net Income | $-231,864,000 | $-551,731,000 | $-513,580,000 | $-101,504,000 | $-170,044,000 |
| Net Margin | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% |
| EPS | $-0.87 | $-2.43 | $-2.60 | $-3.25 | $-5.44 |
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Visit WebsiteEarnings History & Surprises
ALVOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $0.13 | — | — | — |
Q1 2026 | Mar 18, 2026 | $-0.00 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.05 | $-0.02 | -140.0% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.26 | $0.14 | +153.8% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-0.17 | $0.35 | +305.9% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.39 | $-0.24 | +38.5% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.06 | $0.19 | +401.6% | ✓ BEAT |
Q3 2024 | Aug 15, 2024 | $-0.28 | $0.28 | +200.0% | ✓ BEAT |
Q2 2024 | May 21, 2024 | $-0.08 | $-0.89 | -972.3% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $0.15 | $-1.22 | -913.3% | ✗ MISS |
Q4 2023 | Nov 28, 2023 | $-0.29 | $-0.82 | -182.8% | ✗ MISS |
Q3 2023 | Aug 30, 2023 | $-0.14 | $-0.43 | -207.1% | ✗ MISS |
Q2 2023 | May 19, 2023 | — | $-0.33 | — | — |
Q1 2023 | Mar 1, 2023 | — | $-1.29 | — | — |
Q4 2022 | Nov 16, 2022 | — | $-0.04 | — | — |
Q3 2022 | Sep 1, 2022 | — | $-0.54 | — | — |
Q2 2022 | May 16, 2022 | — | $-0.32 | — | — |
Q1 2022 | Mar 30, 2022 | — | $1.28 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.41 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about ALVO
What is ALVO's current stock price?
What is the analyst price target for ALVO?
What sector is Alvotech in?
What is ALVO's market cap?
Does ALVO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALVO for comparison